Bonum Therapeutics Announces A $93M Series A Financing To Advance A Novel And Validated Class Of Conditionally Active Therapies
Bonum Therapeutics Announces A $93M Series A Financing To Advance A Novel And Validated Class Of Conditionally Active Therapies
11/15/22, 12:05 PM
Location
seattle
Money raised
$93 million
Industry
therapeutics
biotechnology
Round Type
series a
Investors
Vivo Capital, Codon Capital, 3x5 Partners, Digitalis Ventures, Roche Venture Fund, Rivervest Venture Partners
Bonum Therapeutics, a biopharmaceutical company using allosteric regulation to create conditionally active and less toxic medicines, today announced a $93 million Series A financing. Bonum is a spinout of Good Therapeutics, which Roche acquired in August 2022 for $250 million upfront plus potential milestone payments. The investor syndicate that financed Good Therapeutics, including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, 3x5 Partners, and Codon Capital participated in the Series A financing, along with a new investor, Vivo Capital. In conjunction with the financing, Mitchell Mutz, Ph.D., of Vivo Capital will be joining the Bonum board of directors.